CYAN CYANOTECH CORP
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 768408 · Fiscal year ends 03/31
Financial factors as of 2025-09-30 (2025Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.5%
TTM net income YoY67.4%
TTM EPS YoY69.9%
Revenue 3-yr CAGR-5.0%
Net income 3-yr CAGR—
Margins
Gross margin32.0%
Operating margin-4.2%
Net margin-7.0%
FCF margin-5.7%
EBITDA margin1.5%
Returns
ROE-20.0%
ROA-7.4%
ROIC (approx.)-5.3%
Asset turnover1.05x
Leverage & solvency
Liabilities / assets66.4%
Debt / equity1.04x
Current ratio1.00x
Interest coverage-1.48x
Cash quality & payout
Operating cash flow / net income0.68x
Accruals ratio-2.4%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q22025-09-30 | 2025Q12025-06-30 | 2025Q4*2025-03-31 | 2024Q32024-12-31 | 2024Q22024-09-30 | 2024Q12024-06-30 | 2024Q4*2024-03-31 | 2023Q32023-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $6.98M | $5.82M | $6.30M | $6.17M | $5.84M | $5.90M | $5.97M | $5.58M |
| Cost of revenue | $4.58M | $4.05M | $4.56M | $3.99M | $4.37M | $4.42M | $5.29M | $3.93M |
| Gross profit | $2.39M | $1.77M | $1.74M | $2.18M | $1.48M | $1.48M | $675,000 | $1.65M |
| R&D expense | $78,000 | $74,000 | $101,000 | $127,000 | $137,000 | $84,000 | $159,000 | $163,000 |
| SG&A expense | $996,000 | $1.30M | $873,000 | $1.01M | $1.24M | $1.27M | $1.08M | $947,000 |
| Operating income | $190,000 | -$753,000 | -$442,000 | -$50,000 | -$975,000 | -$1.04M | -$1.90M | -$848,000 |
| Interest expense | $189,000 | $173,000 | $177,000 | $174,000 | $175,000 | $161,000 | $173,000 | $172,000 |
| Pretax income | $1,000 | -$926,000 | -$619,000 | -$224,000 | -$1.15M | -$1.20M | -$2.08M | -$1.02M |
| Income tax | $0 | $0 | $8,000 | $0 | $0 | $0 | $5,000 | $0 |
| Net income | $1,000 | -$926,000 | -$627,000 | -$224,000 | -$1.15M | -$1.20M | -$2.08M | -$1.02M |
| EBITDA | $536,000 | -$391,000 | -$84,000 | $320,000 | -$602,000 | -$663,000 | -$1.52M | -$453,000 |
| EPS (basic) | 0.00 | -0.13 | — | -0.03 | -0.16 | -0.17 | — | -0.16 |
| EPS (diluted) | 0.00 | — | — | — | -0.16 | -0.17 | — | -0.16 |
| Weighted avg. shares (diluted) | 7.29M | — | — | — | 7.00M | 6.95M | — | 6.55M |
| Balance sheet | ||||||||
| Cash & equivalents | $649,000 | $383,000 | $257,000 | $359,000 | $780,000 | $720,000 | $707,000 | $661,000 |
| Receivables | $2.35M | $1.56M | $1.95M | $1.91M | $1.59M | $2.14M | $2.10M | $2.04M |
| Inventory | $8.38M | $8.11M | $7.79M | $7.75M | $7.18M | $6.96M | $7.31M | $9.12M |
| Current assets | $11.93M | $10.52M | $10.54M | $10.55M | $10.12M | $10.37M | $10.59M | $12.29M |
| PP&E, net | $8.35M | $8.59M | $8.93M | $9.26M | $9.51M | $9.78M | $10.11M | $10.43M |
| Total assets | $24.03M | $23.00M | $23.49M | $23.96M | $23.91M | $24.43M | $25.11M | $27.25M |
| Current liabilities | $11.89M | $10.78M | $10.24M | $9.95M | $9.57M | $10.16M | $8.55M | $8.54M |
| Short-term debt | $7.36M | $7.13M | $6.65M | $6.59M | $6.02M | $6.45M | $5.63M | $5.81M |
| Long-term debt | $1.00M | $1.00M | $1.00M | $1.00M | $1.00M | $0 | $1.00M | $1.00M |
| Total debt | $8.36M | $8.13M | $7.65M | $7.59M | $7.02M | $6.45M | $6.63M | $6.81M |
| Total liabilities | $15.96M | $14.99M | $14.61M | $14.46M | $14.22M | $13.77M | $13.30M | $13.42M |
| Shareholders' equity | $8.06M | $8.00M | $8.88M | $9.50M | $9.69M | $10.66M | $11.81M | $13.83M |
| Net debt | $7.71M | $7.75M | $7.39M | $7.24M | $6.24M | $5.73M | $5.92M | $6.15M |
| Shares outstanding | 7.39M | 7.23M | 7.20M | 7.16M | 7.14M | 6.95M | 6.95M | 6.89M |
| Cash flow statement | ||||||||
| Operating cash flow | $108,000 | -$328,000 | -$57,000 | -$935,000 | -$444,000 | $243,000 | $307,000 | -$1.00M |
| Capital expenditure | $64,000 | $22,000 | $84,000 | $58,000 | $58,000 | $47,000 | $58,000 | $37,000 |
| Free cash flow | $44,000 | -$350,000 | -$141,000 | -$993,000 | -$502,000 | $196,000 | $249,000 | -$1.04M |
| Investing cash flow | -$64,000 | -$22,000 | -$84,000 | -$58,000 | -$58,000 | -$47,000 | -$58,000 | -$37,000 |
| Financing cash flow | $222,000 | $476,000 | $39,000 | $572,000 | $562,000 | -$183,000 | -$203,000 | $462,000 |
| Depreciation & amortization | $346,000 | $362,000 | $358,000 | $370,000 | $373,000 | $378,000 | $383,000 | $395,000 |
| Stock-based compensation | $25,000 | $49,000 | $20,000 | $33,000 | $146,000 | $48,000 | $83,000 | $54,000 |
Free plan shows the latest 8 periods; Pro shows all 62 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.